FDA Lays Out Path For Neoadjuvant Approvals In Breast Cancer
Executive Summary
With breast cancer researchers focusing more and more on treating healthier patients to prevent disease recurrence, FDA lays out a pathway for accelerated approval of new drugs based on pathologic complete response.